The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase III randomized, open-label multicenter trial to evaluate the benefit of leuprorelin acetate for 24 months after radical prostatectomy in patients with high risk of recurrence (AFU-GETUG 20/0310).
Francois Rozet
No relevant relationships to disclose
Muriel Habibian
No relevant relationships to disclose
Jocelyne Berille
No relevant relationships to disclose
Lise Roca
No relevant relationships to disclose
Laurent Salomon
No relevant relationships to disclose
Michel Soulie
No relevant relationships to disclose
Stephane Culine
No relevant relationships to disclose